203695

bpV(phen)

Name: bpV(phen)
Brand: MM

A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.

Synonym(s):

bpV(phen), Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII

Select a Size

All Photos(1)

About This Item

Linear Formula:

K[VO(O₂)₂C₁₂H₈N₂]

CAS Number:

42494-73-5

MDL number:

MFCD32671691

UNSPSC Code:

12352200

NACRES:

NA.77

Product Name

bpV(phen), A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.

SMILES string

[V]=O.[K+].n1c2c3ncccc3ccc2ccc1.OO.OO

InChI

1S/C12H8N2.K.2H2O2.O.V/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1;;2*1-2;;/h1-8H;;2*1-2H;;/q;+1;;;;

InChI key

MQPXOTNOFVCXDA-UHFFFAOYSA-N

assay

≥99% (⁵¹V-NMR)

form

solid

potency

38 nM IC₅₀

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
protect from light

color

yellow

solubility

water: 5 mg/mL

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Related Categories

Bioactive Small Molecule Inhibitors

Biochem/physiol Actions

Cell permeable: no

Primary Target
PTEN

Product does not compete with ATP.

Reversible: no

Disclaimer

Toxicity: Standard Handling (A)

General description

A potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G₂/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC₅₀ = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.

A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G₂/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC₅₀ = 38 nM).

The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.

Other Notes

Schmid, A.C., et al. 2004. FEBS Lett.566, 35.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.

Packaging

Packaged under inert gas

Preparation Note

Unstable in solution; reconstitute just prior to use.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.

Sameer S Chopra et al.

Cell systems, 10(1), 66-81 (2019-12-10)

Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated